Literature DB >> 34980786

The strategy behind Japan's response to COVID-19 from 2020-2021 and future challenges posed by the uncertainty of the Omicron variant in 2022.

Peipei Song1, Takashi Karako2.   

Abstract

Japan has experienced five waves of the COVID-19 pandemic so far. Four states of emergency were declared, and the Tokyo 2020 Olympic (July 23-August 8, 2021) and Paralympic Games (August 24-September 5, 2021) were held during the fifth wave of the pandemic. Although a record 5,773 new cases were reported in Tokyo on August 13, the number abruptly decreased afterwards, and only 9 new cases were confirmed in Tokyo on November 1, 2021. The high vaccination rates (79.2% of the total population has received the first dose and 77.8% has received the second dose as of December 24, 2021) and behavioral changes (such as mask wearing rate in public places remains close to 100%) are considered to be important factors in curbing the spread of the virus. However, the new Omicron variant poses future challenges due to its uncertainty. A cumulative total of 231 cases of the Omicron variant were reported in Japan between November 30 and December 25, 2021. Preliminary data indicated that the Omicron variant could be more contagious but less deadly than the Delta variant. Since mankind may be forced to coexist with COVID-19, efforts such as vaccination campaigns will need to continue and behavioral changes will become increasingly important as the "new normal" to reduce population density and contact with people. This is evinced at least in Japan's successful practices in fighting the past five waves of the pandemic.

Entities:  

Keywords:  COVID-19; Delta variant; Japan; Omicron variant; SARS-CoV-2; behavioral changes; vaccination

Mesh:

Year:  2021        PMID: 34980786     DOI: 10.5582/bst.2021.01560

Source DB:  PubMed          Journal:  Biosci Trends        ISSN: 1881-7815            Impact factor:   2.400


  7 in total

1.  Pediatric Respiratory Virus Infections During the COVID-19 Pandemic in a Region Without Active Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Circulation.

Authors:  Sosuke Kakee; Yoichi Mino; Keisuke Okuno; Daisuke Kawaba; Atsushi Maejima; Noriyuki Namba
Journal:  Yonago Acta Med       Date:  2022-08-29       Impact factor: 1.371

2.  Impact of prioritized vaccinations for the elderly on the COVID-19 pandemic in Japan.

Authors:  Hidetoshi Nomoto; Kayoko Hayakawa; Norio Ohmagari
Journal:  Glob Health Med       Date:  2022-04-30

3.  Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants.

Authors:  Yohei Seki; Yasuo Yoshihara; Kiyoko Nojima; Haruka Momose; Shuetsu Fukushi; Saya Moriyama; Ayumi Wagatsuma; Narumi Numata; Kyohei Sasaki; Tomoyo Kuzuoka; Yoshiyuki Yato; Yoshimasa Takahashi; Ken Maeda; Tadaki Suzuki; Takuo Mizukami; Isao Hamaguchi
Journal:  Med (N Y)       Date:  2022-04-26

4.  Coronavirus disease 2019 transmission and symptoms in young children during the severe acute respiratory syndrome coronavirus 2 Delta variant and Omicron variant outbreaks.

Authors:  Tetsuya Akaishi; Tadashi Ishii
Journal:  J Int Med Res       Date:  2022-05       Impact factor: 1.573

5.  Viral transmissibility of SARS-CoV-2 accelerates in the winter, similarly to influenza epidemics.

Authors:  Shinako Inaida; Richard E Paul; Shigeo Matsuno
Journal:  Am J Infect Control       Date:  2022-05-20       Impact factor: 4.303

Review 6.  Turning point: A new global COVID-19 wave or a signal of the beginning of the end of the global COVID-19 pandemic?

Authors:  Kaixi Ding; Wei Jiang; Chunping Xiong; Ming Lei
Journal:  Immun Inflamm Dis       Date:  2022-04

7.  Prospects of Coffee Leaf against SARS-CoV-2 Infection.

Authors:  Chen-Shiou Wu; Hsiu-Mei Chiang; Yeh Chen; Chung-Yu Chen; Hsiao-Fan Chen; Wen-Chi Su; Wei-Jan Wang; Yu-Chi Chou; Wei-Chao Chang; Shao-Chun Wang; Mien-Chie Hung
Journal:  Int J Biol Sci       Date:  2022-07-11       Impact factor: 10.750

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.